Dexcom Inc. (DXCM)

Name: Dexcom Inc. (DXCM): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Dexcom Inc. (DXCM) reported revenue of $1.3 billion for Q2 FY2026, the quarter ended 30 June 2026, up 13.1% on the same quarter a year earlier. Net income was $249 million, up 38.5% on the year, and diluted earnings per share $0.64. The figures are the company's own, from the 10-Q it filed with the SEC on 30 July 2026.

Revenue$1.3 billionup 13.1%

Net income$249 millionup 38.5%

Diluted EPS$0.64

QuarterQ2 FY2026ended 30 June 2026

Ratios

From the filings

ROE38.1%

ROCE43.5%

Operating margin22.9%

Net margin20.1%

FCF margin28.3%

Interest cover75.94

Debt to equity0.03

Cash conversion1.75

Share count, 1 year-3.8%

Sales CAGR, 3 years17.0%

Profit CAGR, 3 years34.8%

EPS, TTM$2.52

At the close of 21 September 2026

Price$89.17

Market cap$33.7 billion

Stock P/E35.38

Price to book12.84

EV / EBITDA23.20

Dividend yieldn/a

Market cap / sales6.77

52-week high$92.34

52-week low$54.84

Price, 1 year32.2%

Price CAGR, 3 years0.6%

Price CAGR, 5 years-9.0%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Dexcom Inc. files it, at the balance sheet of 31 December 2014, the latest that carries it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on DXCM

Filings	21 in twelve months: 13 current reports (8-K), about 6 officer or director change; 5 regulation fd disclosure; 5 results of operations; 1 shareholder vote; 1 other events
Planned insider sales	26 Form 144 notices in twelve months, $12.4 million; latest 15 September 2026
Options tape	put/call 0.52 by open interest on 23 September 2026; the straddle prices a 4.1% move to 25 September 2026
Holders	10 of the followed funds hold it; largest Baillie Gifford; 4 Schedule 13D or 13G filings in twelve months
Insider trading	28 sales and 2 purchases on Form 4 in twelve months
Congress	0 House trades disclosed in six months
Short interest	17.6 million shares short, 4.31 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	975	1,034	921	1,004	994	1,114	1,036	1,157	1,209	1,260	1,192	1,308
Cost of revenue	352	378	359	378	400	458	447	468	478	467	442	478
Gross profit	623	657	562	627	594	656	589	689	731	793	750	830
Gross margin	64%	63%	61%	62%	60%	59%	57%	60%	60%	63%	63%	63%
R&D	131	136	142	136	135	140	145	148	158	148	145	153
SG&A	285	309	319	333	306	327	310	328	331	322	350	359
Operating income	206	217	101	158	152	189	134	213	242	323	255	318
Operating margin	21%	21%	11%	16%	15%	17%	13%	18%	20%	26%	21%	24%
Interest expense	4.9	4.9	4.6	4.8	4.7	4.9	4.7	4.7	4.7	4.2	3.1	3.0
Pre-tax income	240	246	132	188	177	211	154	241	352	341	270	318
Tax rate	50%	-4%	-10%	24%	24%	28%	32%	25%	19%	22%	26%	22%
Net income	121	256	146	144	135	152	105	180	284	267	200	249
Net margin	12%	25%	16%	14%	14%	14%	10%	16%	23%	21%	17%	19%
Diluted EPS	$0.29	$0.61	$0.36	$0.35	$0.34	$0.37	$0.27	$0.45	$0.70	$0.67	$0.51	$0.64
Operating cash flow	269	134	209	279	200	301	184	303	660	294	526	269
Capital expenditure	50.4	52.5	56.9	66.1	111	125	87.0	94.1	80.5	102	76.6	84.7
Free cash flow	219	81.1	152	213	88.3	177	96.8	209	579	192	449	184
Buybacks	0.0	n/a	n/a	n/a	750	n/a	n/a	n/a	187	n/a	n/a	n/a
Shares outstanding	386m	385m	396m	401m	391m	391m	392m	392m	390m	385m	386m	377m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020 †	FY2021 †	FY2022 †	FY2023	FY2024	FY2025	TTM
Revenue	259	402	573	718	1,032	1,476	1,927	2,448	2,910	3,622	4,033	4,662	4,969
Cost of revenue	82.9	124	195	226	368	544	647	768	1,027	1,333	1,595	1,860	1,865
Gross profit	176	278	378	492	664	932	1,280	1,680	1,883	2,289	2,438	2,802	3,104
Gross margin	68.0%	69.3%	66.0%	68.5%	64.4%	63.1%	66.4%	68.6%	64.7%	63.2%	60.5%	60.1%	62.5%
Research and development	69.4	138	156	185	200	274	360	517	484	506	552	599	604
Selling, general and administrative	128	198	286	349	433	516	618	810	1,008	1,185	1,286	1,291	1,361
Operating income	-21.5	-57.1	-63.9	-42.5	-186	142	300	266	391	598	600	912	1,139
Operating margin	-8.3%	-14.2%	-11.1%	-5.9%	-18.1%	9.6%	15.5%	10.9%	13.4%	16.5%	14.9%	19.6%	22.9%
Interest expense	0.8	0.4	0.7	12.8	22.7	60.3	17.7	18.8	18.6	20.3	19.0	18.3	15.0
Pre-tax income	-22.3	-57.5	-64.9	-48.6	-126	104	298	257	391	710	709	1,088	1,280
Income tax	0.1	0.1	0.7	1.6	0.6	3.1	-252	39.9	49.6	169	133	252	280
Effective tax rate	n/a	n/a	n/a	n/a	n/a	3.0%	-84.5%	15.5%	12.7%	23.8%	18.7%	23.2%	21.9%
Net income	-22.4	-57.6	-65.6	-50.2	-127	101	550	217	341	542	576	836	1,000
Net margin	-8.6%	-14.3%	-11.4%	-7.0%	-12.3%	6.8%	28.5%	8.9%	11.7%	14.9%	14.3%	17.9%	20.1%
Diluted EPS	-$0.30	-$0.72	-$0.78	-$0.58	-$1.44	$1.10	$5.06	$1.55	$0.82	$1.30	$1.42	$2.09	$2.52
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020 †	FY2021 †	FY2022 †	FY2023	FY2024	FY2025	TTM
Operating cash flow	23.6	49.0	56.2	92.0	123	314	476	442	670	748	990	1,441	1,749
Capital expenditure	16.2	33.3	55.7	66.0	67.1	180	199	389	365	237	359	364	344
Free cash flow	7.4	15.7	0.5	26.0	56.1	134	277	53.3	305	512	631	1,077	1,405
Free cash flow margin	2.9%	3.9%	0.1%	3.6%	5.4%	9.1%	14.4%	2.2%	10.5%	14.1%	15.6%	23.1%	28.3%
Depreciation and amortisation	8.4	10.8	15.0	16.1	29.1	48.7	67.1	102	156	186	218	252	264
Share-based compensation	50.0	82.7	111	106	102	103	119	113	126	151	170	160	162
Buybacks	n/a	n/a	0.0	0.0	100	0.0	0.0	0.0	558	689	750	500	n/a
Diluted shares, weighted	n/a	n/a	n/a	86m	88m	92m	98m	100m	428m	426m	413m	406m	390m
Shares outstanding at period end	77m	82m	85m	87m	90m	92m	96m	97m	386m	385m	391m	385m	377m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020 †	FY2021 †	FY2022 †	FY2023	FY2024	FY2025	TTM
Total assets	185	292	403	904	1,916	2,395	4,290	4,933	5,392	6,264	6,484	6,340	6,455
Cash and equivalents	71.8	86.1	94.5	442	1,137	446	818	1,053	642	566	606	918	1,105
Receivables	42.4	74.1	102	134	227	286	428	514	713	974	1,006	1,216	1,258
Inventory	16.0	35.2	45.4	45.2	70.7	120	235	357	307	560	543	629	726
Goodwill	3.2	3.7	11.3	12.1	18.7	18.6	19.3	26.5	25.7	25.2	22.8	24.2	24.1
Long-term debt	4.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating lease liabilities	n/a	n/a	n/a	n/a	0.0	72.4	102	98.6	94.6	80.1	65.0	73.4	82.6
Finance lease liabilities	n/a	n/a	n/a	n/a	n/a	14.4	54.0	57.0	59.6	58.6	58.5	53.8	52.3
Shareholders' equity	140	221	284	419	663	883	1,552	2,042	2,132	2,069	2,103	2,746	2,621
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	27.8%	19.3%	17.0%	15.5%
Profit growth, compounded	n/a	8.8%	34.8%	74.9%
Return on equity, average	10.3%	22.1%	28.0%	30.5%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Surgical & Medical Instruments & Apparatus

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Stryker Corp. SYK	$105.2 billion	28.41	15.5%	21.4%	8.5%	0.62	1.3%
3M Co. MMM	$85.1 billion	29.30	101.5%	18.4%	2.3%	3.69	1.8%
Boston Scientific Corp. BSX	$63.4 billion	17.70	14.7%	19.8%	13.5%	0.44	n/a
Becton Dickinson & Co. BDX	$49.2 billion	54.59	3.9%	9.6%	-2.6%	0.55	2.3%
Dexcom Inc. DXCM	$33.7 billion	35.38	38.1%	22.9%	15.5%	0.03	n/a
Resmed Inc. RMD	$32.3 billion	21.44	23.1%	33.4%	9.9%	0.10	1.1%
West Pharmaceutical Services Inc. WST	$25.5 billion	46.32	18.9%	20.5%	12.4%	0.07	0.2%
Solventum Corp. SOLV	$15.1 billion	10.85	29.9%	25.0%	-0.9%	1.06	n/a
Baxter International Inc. BAX	$11.9 billion	n/a	-17.1%	-2.4%	5.4%	1.54	2.3%
Insulet Corp. PODD	$9.7 billion	26.37	26.4%	16.9%	29.4%	0.65	n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	30 July 2026	EDGAR
10-Q	31 March 2026	30 April 2026	EDGAR
10-K	31 December 2025	12 February 2026	EDGAR
10-Q	30 September 2025	30 October 2025	EDGAR
10-Q	30 June 2025	30 July 2025	EDGAR
10-Q	31 March 2025	1 May 2025	EDGAR
10-K	31 December 2024	18 February 2025	EDGAR
10-Q	30 September 2024	24 October 2024	EDGAR
10-Q	30 June 2024	25 July 2024	EDGAR
10-Q	31 March 2024	25 April 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install